Researchers have directly imaged the electrostatic landscape inside a single moiré unit cell for the first time, using a new atomic-scale sensor built from a single defect in a two-dimensional ...

outline.png validation.png MLIP_LiNbO3_VASP_LAMMPS / LAMMPS / LN_hexagonal_unit_cell.data Cannot retrieve latest commit at this time.

CSL Seqirus, the vaccine unit of Australian biotech CSL, has signed a pact to provide Saudi Arabia with cell-based influenza shots and help establish its production in-country. The move forms part of ...

Galapagos is planning to wind down its cell therapy business, completing a whiplash change that saw the biotech go from focusing on the modality to ditching it in six months. Belgium-based Galapagos ...

Ozempic maker Novo Nordisk (NVO) is closing its cell therapy division as part of a major restructuring drive initiated under the company’s new CEO, Mike Doustdar, Bloomberg News reported on Thursday, ...

(Reuters) -Novo Nordisk has decided to discontinue its cell therapy research and development efforts, a spokesperson for the Danish drugmaker told Reuters on Friday. Bloomberg News first reported on ...

Add Yahoo as a preferred source to see more of our stories on Google. MIT scientists built SCIGEN, an AI system that speeds up quantum material discovery by following geometric rules. (CREDIT: The ...

Scientists have created an artificial intelligence tool called SCIGEN that can potentially speed up the hunt for novel quantum materials. Such unusual substances, displaying odd electronic and ...

Hexagon shares rose after the Swedish measurement-technology group said it agreed to sell its design and engineering business to Cadence Design Systems for 2.7 billion euros ($3.15 billion). Shares in ...

(Reuters) -Cadence Design said on Thursday it will buy the design and engineering business of Stockholm-based Hexagon AB for 2.7 billion euros ($3.16 billion), to expand its customer base and scale up ...

Gilead Sciences' Kite Pharma has cut off a collaboration with Shoreline Biosciences, ending a research collaboration on off-the-shelf cell therapies that was valued at more than $2.3 billion. The deal ...